Active	Status	Sponsor type	Region	Phase	Filter
8 Active 5 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anderson, Donald
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Active, not recruiting	3	1667	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	04/24	03/26
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression	Completed	2	197	Canada, US	Liafensine, Placebo	Denovo Biopharma LLC	Treatment Resistant Depression	02/24	03/24
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24
PRMRP-FPA2, NCT04562896: Iterative Design of Custom Dynamic Orthoses to Reduce Articular Contact Stress	Completed	N/A	22	US	Custom Carbon Fiber Dynamic Orthosis (CDO), Ankle Foot Orthosis	University of Iowa, University of Delaware, Bio-Mechanical Composites, Fabtech Systems	Ankle Fractures, Post-traumatic Osteoarthritis, Osteoarthritis Ankle	10/23	10/23
PRMRP FPA CT, NCT05209347: Custom Dynamic Orthoses to Reduce Articular Contact Stress	Withdrawn	N/A	20	US	Carbon Fiber Custom Dynamic Orthosis (CDO), Ankle Foot Orthosis (AFO)	University of Iowa	Ankle Fractures, Post-traumatic Osteoarthritis, Osteoarthritis Ankle	12/25	12/25

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Anderson, Donald
CHALLENGE-MIG, NCT05127486: A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine Enrollment initiated in combination with Emgality for episodic migraine Nov 2021 - Nov 2021: Enrollment initiated in combination with Emgality for episodic migraine	Completed	4	580	US	Galcanezumab, LY2951742, Rimegepant, Placebo	Eli Lilly and Company	Migraine, Episodic Migraine	05/23	05/23
TRAILRUNNER-ALZ 1, NCT05463731: A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease	Active, not recruiting	3	1667	Japan, US	Remternetug (IV), LY3372993, Remternetug (SC), Placebo	Eli Lilly and Company	Alzheimer's Disease	04/24	03/26
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease	Terminated	3	1027	Europe, Canada, Japan, US, RoW	Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo	Biogen, Biogen Idec Research Limited	Alzheimer's Disease	08/24	08/24
NCT05026866: A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)	Recruiting	3	2196	Japan, US	Donanemab, LY3002813, Placebo	Eli Lilly and Company	Alzheimer Disease	11/27	11/27
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression	Completed	2	197	Canada, US	Liafensine, Placebo	Denovo Biopharma LLC	Treatment Resistant Depression	02/24	03/24
NCT04845178: Investigation of Safety and Efficacy of ABP-450 for Migraine Prevention in Adults	Completed	2	797	NA	ABP-450, prabotulinumtoxinA, Placebo, 0.9% sodium chloride, saline	AEON Biopharma, Inc., PPD	Migraine	06/24	08/24
PRMRP-FPA2, NCT04562896: Iterative Design of Custom Dynamic Orthoses to Reduce Articular Contact Stress	Completed	N/A	22	US	Custom Carbon Fiber Dynamic Orthosis (CDO), Ankle Foot Orthosis	University of Iowa, University of Delaware, Bio-Mechanical Composites, Fabtech Systems	Ankle Fractures, Post-traumatic Osteoarthritis, Osteoarthritis Ankle	10/23	10/23
PRMRP FPA CT, NCT05209347: Custom Dynamic Orthoses to Reduce Articular Contact Stress	Withdrawn	N/A	20	US	Carbon Fiber Custom Dynamic Orthosis (CDO), Ankle Foot Orthosis (AFO)	University of Iowa	Ankle Fractures, Post-traumatic Osteoarthritis, Osteoarthritis Ankle	12/25	12/25